Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

mer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business.  Unless otherwise noted, Amgen is providing this information as of May 25, 2011 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as e
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 OmPrompt ... Millionen £ investiert hat, um die weltweite ... Pharma- und Logistikbranche zu erfüllen. Albion wird ... (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... sein beschleunigtes Wachstum mit Investitionen in seine ...
(Date:7/28/2014)... VILLAGE, Nev. , July 28, 2014 PDL ... that the Company will release its second quarter 2014 financial ... August 11, 2014, after market close. PDL,s management will host ... Eastern Time to discuss the financial results.  A slide presentation ... link on the PDL website. Conference Call Details ...
(Date:7/28/2014)... Germany and LONDON ... , Collaboration aims to create and commercialize companion ... the use of IRESSA  for non-small cell lung cancer ... QIAGEN,s FDA-approved  therascreen   EGFR test and is planned to run on ... instruments  Project enabled by AstraZeneca master framework ...
Breaking Medicine Technology:OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... Consumer Healthcare Products Association (CHPA) released the following ... passing a real-time, stop-sale system that allows law-abiding ... pseudoephedrine (PSE), while stopping sales that exceed the ... real-time, stop-sale system is a victory for law-abiding ...
... HeartWare International, Inc. (NASDAQ: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... Eastern Time on Wednesday, June 22, 2011.  The conference ...
Cached Medicine Technology:HeartWare to Present at the Wells Fargo 2011 Healthcare Conference 2
(Date:7/28/2014)... new study, published in the July, 2014, issue ... Institute by Northwestern Medicine researchers, sheds new ... popularity of endoscopic resection in the treatment of ... more traditional surgical resection, while more invasive, provided ... survival rate for patients than endoscopic resection, which ...
(Date:7/28/2014)... Smart phones and mobile devices are on the cusp ... apps capable of providing everything from cardiac measurements to ... to medical treatment and control costs, several health law ... of Medicine (NEJM) report that more oversight is ... to ensure consumer confidence and safety. Out of some ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
(Date:7/28/2014)... Abington, PA (PRWEB) July 28, 2014 ... solutions provider for the healthcare industry, went live in ... and surpassed the basic standards of excellence that comprise ... specifically for excellence in Healthcare. , “What pleases me ... both the content and usability categories,” said Joshua Snow, ...
(Date:7/28/2014)... 2014 Irresistible infants have met their match with ... The online gifting company specializes in homemade chicken noodle soup and ... Baby package starts with home-from-the-hospital essentials every new parent will love:, ... 6 rolls , 6 cookies , a ... is ready to heat and eat upon delivery, so parents can ...
Breaking Medicine News(10 mins):Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Booming mobile health app market needs more FDA oversight for consumer safety, confidence 2Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2Health News:Abington Health Website Named Best in Class 2Health News:Spoonful of Comfort Announces "New Baby" Gift Package 2
... genetic links, but urge further study , WEDNESDAY, Oct. ... that might be associated with autism have been identified ... a single-letter change on chromosome 5 near a gene ... the growth of neurons and their long progressions, called ...
... 7 Each year, an estimated 800,000 ... in which the victims survive, but their lives, and ... Brain injury victims can suffer from a multitude of ... depression and sleep disturbances. , Careforward , ...
... Crawford & Company,s (NYSE: CRDA ; CRDB) ... under the brand name of Broadspire, a Crawford company, ... , Crawford (NYSE: CRDA ; CRDB), the world,s ... latest expansion of the Broadspire brand at the Federation ...
... Healthcare, one of the nation,s first and leading providers ... nephrology research, today announced their sponsorship of the National ... , The Author,s Luncheon is San Francisco,s premier ... captivated by the fascinating stories, wit and humor of ...
... , BOCA RATON, Fla., Oct. 7 Coverall Health-Based Cleaning ... announced it has been recognized as one of the ... Franchising Initiative (NMFI) for the third year in a ... "Franchising Today" section of USA Today, the national daily ...
... Henry Ford Hospital have identified tumor-suppressing genes that may ... survival for laryngeal cancer patients than current standards. ... specific receptor 1) gene and the HIC1 (hypermethylated in ... and shorter survival, respectively, for patients with the disease. ...
Cached Medicine News:Health News:Potential Pieces of Autism Puzzle Revealed 2Health News:Mingling, Martinis & Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:Satellite Healthcare Partners With the National Kidney Foundation for the 21st Annual San Francisco Author's Luncheon 2Health News:Coverall Named Among '50 Top Franchises for Minorities' for Third Consecutive Year 2Health News:Genes signal late-stage laryngeal cancer, poorer outcome 2
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... Unique to the Medtronic Hall, the aortic and ... In the aortic position, the disc opens to ... valve opens to 70 to minimize regurgitation. Designed ... the surgeon to align the leading edge of ...
... Pipettor , , The Shortyavailable with both ... how our face-to-face relationship with the scientific community ... make pipetting easier and more effective., Shorter ... Gets you closer to the working area ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: